Medical Oncology

CLL

Questions discussed in this category

Would it be reasonable to offer a patient with CLL a treatment break from acalabrutinib or any BTK inihibitor after a period of time, assuming good response?

It is understood that the trials experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about real...

0 Answers available

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

0 Answers available

Would you ever consider using ibrutinib in CLL patients who have received first line acalabrutinib and then progressed?

3 Answers available

What factors do you take into account for recommending venetoclax/obtinutuzumab vs BTK inhibitors vs chemotherapy in front line therapy for CLL?

Are there specific clinical, patient, or disease factors you focus on?

4 Answers available

Would you extrapolate results from ELEVATE-RR study to favor use of acalabrutinib as first-line therapy in treatment-naive CLL?

Does this data change your preferred first line treatment regimens when considering other options such as mAb combos, cytotoxic chemotherapy?

3 Answers available

Do you find ELEVATE-RR data and study design compelling to start preferentially using acalabrutinib over ibrutinib?

Is the non-inferiority margin of 1.429 sufficient, how was this selected? Is the open label (rather than blinded) study design of any concern? Is th...

4 Answers available

Do you routinely offer fungal prophylaxis for patients on BTK inhibitors?

Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?

3 Answers available

What is your approach to CLL in patients with atrial fibrillation and/or on anticoagulation?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

3 Answers available

Given results of the ELEVATE-RR study, would you consider use of acalabrutinib in all patients with previously treated CLL, or restrict it to certain patient populations?

Such as patients with specific underlying cardiovascular risk factors or other medical comorbidities?

3 Answers available

For frail patients with cardiac co-morbidities and relapsed CLL with high cytogenetic risk, what are some considerations for using continuous acalabrutinib over fixed duration therapies such as venetoclax/rituximab?

2 Answers available

What would be your choice of therapy in a fit patient with relapsed CLL previously treated with bendamustine and rituximab who does not want BTK inhibitor therapy?

Relapsed disease occurred 3.5 years after initial treatment

2 Answers available

What is your preferred frontline treatment for CLL in young patients < 50 years old?

2 Answers available

How would you treat a de novo CLL with WBC of 1,000,000 and no overt signs of leukostasis?

1 Answer available

Do you ever discontinue ibrutinib in patients with CLL who have a good response?

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...

1 Answer available

What front line therapy would you recommend for a patient with CLL on chronic dual antiplatelet therapy?

How would your choice of therapy differ (if at all) for high vs low risk disease? Would the specific anti-platelet agents used influence your choice ...

0 Answers available

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor?

4 Answers available